Bidirectional Cardiorenal Interactions in Type 2 Diabetes

We read with great interest the recent study by Sharma et al¹ reporting a bidirectional relationship between worsening kidney function (WKF) and cardiovascular outcomes in patients with type 2 diabetes and atherosclerotic cardiovascular disease. These findings underscore the close interdependence of cardiac and renal dysfunction.

Several considerations may further inform the interpretation of these results. First, the post hoc design limits causal inference, particularly in the absence of adjustment for time-dependent therapeutic changes following cardiovascular events. Second, defining WKF as a ≥40% decline in estimated glomerular filtration rate may fail to capture earlier, clinically meaningful renal deterioration. The modest decline in kidney function preceding cardiovascular events suggests that subclinical changes may carry prognostic significance.²

Third, the reported bidirectionality should be interpreted with caution. Temporal associations do not necessarily imply reciprocal causation, and shared pathophysiological mechanisms—including hemodynamic perturbation, inflammation, and neurohormonal activation—may underlie both renal and cardiovascular deterioration.³ The strong association between hospitalization for heart failure and subsequent WKF may, in part, reflect these overlapping processes.⁴

Importantly, lipid parameters were not incorporated into the analyses. Dyslipidemia is a well-established determinant of both atherosclerotic progression and renal dysfunction.⁵ Variability in lipid profiles or lipid-lowering therapy may therefore represent an important source of residual confounding. Incorporation of lipid metrics in future analyses may help clarify whether lipid-related pathways contribute to the observed cardiorenal interactions and whether lipid-lowering interventions modify this risk trajectory.

Finally, these findings should be interpreted in the context of contemporary care. The TECOS trial predates the widespread use of sodium-glucose cotransporter 2 inhibitors, which have demonstrated substantial cardiorenal benefits. Whether early initiation of these therapies can attenuate the bidirectional risk between WKF and cardiovascular events remains an important question. In addition, the association between WKF and severe hypoglycemia highlights a vulnerable clinical phenotype that may require individualized therapeutic strategies.

In conclusion, Sharma et al provide important evidence linking kidney dysfunction and cardiovascular events in a bidirectional manner. Prospective studies incorporating comprehensive metabolic profiling and contemporary therapies are needed to refine causal inference and guide clinical management.